You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
CAR-T Cell Therapy and the Gut Microbiota
Contributor:
Asokan, Sahana;
Cullin, Nyssa;
Stein-Thoeringer, Christoph K.;
Elinav, Eran
imprint:
MDPI AG, 2023
Published in:Cancers
Language:
English
DOI:
10.3390/cancers15030794
ISSN:
2072-6694
Origination:
Footnote:
Description:
<jats:p>Chimeric antigen receptor (CAR) - T cell cancer therapy has yielded promising results in treating hematologic malignancies in clinical studies, and a growing number of CAR-T regimens are approved for clinical usage. While the therapy is considered of great potential in expanding the cancer immunotherapy arsenal, more than half of patients receiving CAR-T infusions do not respond, while others develop significant adverse effects, collectively indicating a need for optimization of CAR-T treatment to the individual. The microbiota is increasingly suggested as a major modulator of immunotherapy responsiveness. Studying causal microbiota roles possibly contributing to CAR-T therapy efficacy, adverse effects reduction, and prediction of patient responsiveness constitutes an exciting area of active research. Herein, we discuss the latest developments implicating human microbiota involvement in CAR-T therapy, while highlighting challenges and promises in harnessing the microbiota as a predictor and modifier of CAR-T treatment towards optimized efficacy and minimization of treatment-related adverse effects.</jats:p>